Hyderabad: Covaxin which was developed accidentally had an overall efficacy of 77.8% against the symptomatic Covid-19 and 65.2% effective against the Delta variant (B.1.617.2) which was first detected in India, the developer Bharat Biotech said on Saturday , Also, Covaxin was 93.4% effective against Covid-19 disease symptoms that were severe and offered protection of 63.6% against Asimptomatic Covid-19, Bharat Biotech said revealing the final analysis of phase III trials conducted at 25,800 participants aged between 18 and 98 year.
India.
This vaccine also shows a higher efficacy of 79.4% in those under 60 years old compared to 67.8% in those aged 60 years and over.
The results were published in the Preprint of the Medrxiv server, which published research work before peer reviews.
The company said the overall efficacy of 77.8% has arrived after 130 cases confirmed by Covid-19 was reported among the trial participants, which included 24 participants who received both covaxin doses and 106 volunteers who received placebo shots.
Shows that covaxin is well tolerated without anaphylaxis case or death related to the vaccine reported, said: “The overall level of side effects observed in the Covaxin is lower than the other Covid-19 vaccine.
Safety analysis shows the side effects reported similar to placebo, With 12% of the subjects that experienced general side effects and less than 0.5% of the subject felt serious side effects.
“Bharat Biotech also said Covaxin was the first to report promising efficacy of the asymptomatic infection of QPCR testing, which would help reduce the transmission of the disease , “There is no licensed Sarscov-2 vaccine has reported efficacy of asymptomatic infections in randomized controlled trials based on QPCR testing,” he said.
“Safety and efficacy of the Covaxin reading set the ability of India and the world’s developing countries to focus on the innovation and development of new products.
We are proud to state that innovation from India will now be available to protect the global population,” Chairman of Bharat Biotech and Managing Director Dr.
Krishna Ella, adding that Covaxin has been specifically.
Designed to meet the needs of global distribution chains.
Calling Covaxin A “effective highest international standard vaccine”, Director General of the Indian Council of the Medical Research Council (ICMR) Dr.
Balram Bhargava said the successful development has consolidated the position of the Indian academics and industry in the global arena.
Making a Covaxin development trip as “encouraging”, Dr.
Priya Abraham, Director, National Institute of Virology (NIV), Pune, said: “The manufacture of this vaccine is entirely in Indian land is a matter of great pride for every Indian.” According to Dr.
Bhargava, who is also a secretary of the Ministry of Health Research, Covaxin will not only benefit Indian citizens but will also help protect the global community because it works well to all viral variants.
Covaxin has been evaluated against several variants of concern through neutralizing antibody responses, with data published in peer-reviewed journals, adding Dr.
Abraham.
This variant includes B.1.617.2 (DELTA), B.1.617.1 (Kappa), B.1.1.7 (Alpha), B.1.351 (Beta), P2-B.1.28 (Gamma).
ICMR & NIV collaborated with hyderabad-based vaccine makers in the development of an inactive virus vaccine.